Cancer drug developer Tango Therapeutics is adding $175 million more to its coffers in cash and equity, funds the company says will help it get its lead program into the clinic in 18 months.
The money includes $50 million in equity financing, $20 million of that from Gilead Sciences (NASDAQ: GILD), plus another $125 million committed by Gilead in the form of an upfront payment.
Cambridge, MA-based Tango has been working with Gilead to advance its cancer research since 2018, and Foster City, CA-based Gilead’s decision to invest comes with an agreement to expand that partnership, which initially kicked off… Read more »
UNDERWRITERS AND PARTNERS
